462 related articles for article (PubMed ID: 26271842)
1. Factors Associated with Recurrence of Age-Related Macular Degeneration after Anti-Vascular Endothelial Growth Factor Treatment: A Retrospective Cohort Study.
Kuroda Y; Yamashiro K; Miyake M; Yoshikawa M; Nakanishi H; Oishi A; Tamura H; Ooto S; Tsujikawa A; Yoshimura N
Ophthalmology; 2015 Nov; 122(11):2303-10. PubMed ID: 26271842
[TBL] [Abstract][Full Text] [Related]
2. Two-year visual outcome of ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
Hata M; Tsujikawa A; Miyake M; Yamashiro K; Ooto S; Oishi A; Nakanishi H; Takahashi A; Yoshimura N
Graefes Arch Clin Exp Ophthalmol; 2015 Feb; 253(2):221-7. PubMed ID: 24961698
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment.
Yamashiro K; Tomita K; Tsujikawa A; Nakata I; Akagi-Kurashige Y; Miyake M; Ooto S; Tamura H; Yoshimura N
Am J Ophthalmol; 2012 Jul; 154(1):125-36. PubMed ID: 22465368
[TBL] [Abstract][Full Text] [Related]
4. Retinal Pigment Epithelial Atrophy in Neovascular Age-Related Macular Degeneration After Ranibizumab Treatment.
Kuroda Y; Yamashiro K; Tsujikawa A; Ooto S; Tamura H; Oishi A; Nakanishi H; Miyake M; Yoshikawa M; Yoshimura N
Am J Ophthalmol; 2016 Jan; 161():94-103.e1. PubMed ID: 26432927
[TBL] [Abstract][Full Text] [Related]
5. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration.
Smailhodzic D; Muether PS; Chen J; Kwestro A; Zhang AY; Omar A; Van de Ven JP; Keunen JE; Kirchhof B; Hoyng CB; Klevering BJ; Koenekoop RK; Fauser S; den Hollander AI
Ophthalmology; 2012 Nov; 119(11):2304-11. PubMed ID: 22840423
[TBL] [Abstract][Full Text] [Related]
6. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.
Abedi F; Wickremasinghe S; Richardson AJ; Islam AF; Guymer RH; Baird PN
Ophthalmology; 2013 Aug; 120(8):1641-8. PubMed ID: 23582991
[TBL] [Abstract][Full Text] [Related]
7. ARMS2 A69S polymorphism is associated with the number of ranibizumab injections needed for exudative age-related macular degeneration in a pro re nata regimen during 4 years of follow-up.
Valverde-Megías A; Veganzones-de-Castro S; Donate-López J; Maestro-de-Las-Casas ML; Megías-Fresno A; García-Feijoo J
Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2091-2098. PubMed ID: 28744656
[TBL] [Abstract][Full Text] [Related]
8. Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
Kawashima Y; Oishi A; Tsujikawa A; Yamashiro K; Miyake M; Ueda-Arakawa N; Yoshikawa M; Takahashi A; Yoshimura N
Graefes Arch Clin Exp Ophthalmol; 2015 Sep; 253(9):1471-7. PubMed ID: 25391986
[TBL] [Abstract][Full Text] [Related]
9. Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age-related macular degeneration.
Cobos E; Recalde S; Anter J; Hernandez-Sanchez M; Barreales C; Olavarrieta L; Valverde A; Suarez-Figueroa M; Cruz F; Abraldes M; Pérez-Pérez J; Fernández-Robredo P; Arias L; García-Layana A
Acta Ophthalmol; 2018 Mar; 96(2):e201-e212. PubMed ID: 28926193
[TBL] [Abstract][Full Text] [Related]
10. Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration.
Shin JY; Kwon KY; Byeon SH
Acta Ophthalmol; 2015 Sep; 93(6):524-32. PubMed ID: 25581639
[TBL] [Abstract][Full Text] [Related]
11. Association of the CFH Y402H Polymorphism with the 1-Year Response of Exudative AMD to Intravitreal Anti-VEGF Treatment in the Brazilian Population.
Medina FMC; Motta AALD; Takahashi WY; Carricondo PC; Motta MMDS; Melo MB; Vasconcellos JPC
Ophthalmic Res; 2019; 61(3):168-173. PubMed ID: 28641277
[TBL] [Abstract][Full Text] [Related]
12. Combined effects of genetic and non-genetic risk factors affect response to ranibizumab in exudative age-related macular degeneration.
Piermarocchi S; Miotto S; Colavito D; Leon A; Segato T
Acta Ophthalmol; 2015 Sep; 93(6):e451-7. PubMed ID: 25402348
[TBL] [Abstract][Full Text] [Related]
13. Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study).
Bhisitkul RB; Desai SJ; Boyer DS; Sadda SR; Zhang K
Ophthalmology; 2016 Jun; 123(6):1269-77. PubMed ID: 26996339
[TBL] [Abstract][Full Text] [Related]
14. Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials.
; Maguire MG; Martin DF; Ying GS; Jaffe GJ; Daniel E; Grunwald JE; Toth CA; Ferris FL; Fine SL
Ophthalmology; 2016 Aug; 123(8):1751-1761. PubMed ID: 27156698
[TBL] [Abstract][Full Text] [Related]
15. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.
Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T
Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration.
Hermann MM; van Asten F; Muether PS; Smailhodzic D; Lichtner P; Hoyng CB; Kirchhof B; Grefkes C; den Hollander AI; Fauser S
Ophthalmology; 2014 Apr; 121(4):905-10. PubMed ID: 24365177
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Response to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment of Age-Related Macular Degeneration.
Shah AR; Williams S; Baumal CR; Rosner B; Duker JS; Seddon JM
Am J Ophthalmol; 2016 Mar; 163():154-166.e8. PubMed ID: 26705092
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD.
Cruz-Gonzalez F; Cabrillo-Estévez L; López-Valverde G; Cieza-Borrella C; Hernández-Galilea E; González-Sarmiento R
Graefes Arch Clin Exp Ophthalmol; 2014 Mar; 252(3):469-75. PubMed ID: 24522370
[TBL] [Abstract][Full Text] [Related]
19. Subfoveal Choroidal Thickness in Eyes with Neovascular Age-Related Macular Degeneration Treated with Anti-Vascular Endothelial Growth Factor Agents.
Kanadani TCM; Veloso CE; Nehemy MB
Ophthalmologica; 2018; 240(4):200-207. PubMed ID: 29768266
[TBL] [Abstract][Full Text] [Related]
20. Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme.
Heimes B; Lommatzsch A; Zeimer M; Gutfleisch M; Spital G; Dietzel M; Pauleikhoff D
Graefes Arch Clin Exp Ophthalmol; 2011 May; 249(5):639-44. PubMed ID: 20890777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]